摘要
目的探讨基质金属蛋白酶-9(MMP-9)与扩大时间窗至发病6 h内急性脑梗死重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗的关系。方法对70例本院神经内科扩大时间窗内行rt-PA静脉溶栓的急性脑梗死患者分别测定溶栓前后的血浆MMP-9水平,并与急性脑梗死非溶栓对照组比较。结果急性脑梗死患者溶栓组、非溶栓对照组入院12 h后血浆MMP-9水平和入院时比较都有显著差异(P<0.05);有出血转化者MMP-9水平皆较无出血转化为高(P<0.05),但无论有无出血转化溶栓组、非溶栓对照组间入院时、入院12 h后MMP-9水平比较无明显差异(P>0.05)。结论急性脑梗死MMP-9表达水平与出血转化相关,但这一改变可能与溶栓治疗无关。
Objective To explore the relationship between matrix metalloproteinase 9 (MMP-9)and re-combinant tissue plasminogen activator (rt-PA)thrombolysis therapy at the expanding time window 6 hours of acute cerebral infarction.Methods 70 patients with acute cerebral infarction who were treated with rt-PA in-travenous thrombolysis at the expanding time window were included,and the plasma MMP-9 levels of these pa-tients were measured before and after thrombolytic therapy in comparison to the control non-thrombolytic group.Results The patients with acute cerebral infarction,both thrombolytic group and non-thrombolytic group after admission 12 hours plasma MMP-9 levels have significant difference (P 〈 0.05 )compared with those at admission;The MMP-9 levels with hemorrhagic Complications were higher (P 〈0.05)than non-hem-orrhagic Complications,but regardless of with and without hemorrhagic transformation in thrombolytic group and non-thrombolytic group between admission and after 12 hours,MMP-9 level was not statistically signifi-cant (P &gt;0.05).Conclusions The expression level of MMP-9 in acute cerebral infarction related with hemor-rhage transformation,but this change might not be associated with thrombolytic therapy.
出处
《卒中与神经疾病》
2015年第1期18-20,共3页
Stroke and Nervous Diseases
基金
上海市浦东新区卫生系统领先人才培养基金(PWR12010-02)
上海市浦东新区卫生系统重点学科建设基金(PWZXK2010-03)
关键词
基质金属蛋白酶-9
脑梗死
溶栓
重组组织型纤溶酶原激活剂
Matrix metalloproteinase-9
Acute cerebral infarction
Thrombolytic therapy
Recombi-nant tissue type plasminogen activator